Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prostatype Genomics ABOSTO:PROGEN +3.46%23 Earnings Yield (Joel Greenblatt) % is -303.03% as of Dec. 2025. GuruFocus rates OSTO:PROGEN with a GF Score™ of 23/100 and a GF Value™ of kr0.04 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Prostatype Genomics AB ranks worse than 97.65% on this metric.
Prostatype Genomics AB's Enterprise Value for the quarter that ended in Dec. 2025 was kr13.99 Mil.
Prostatype Genomics AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was kr-42.89 Mil. Prostatype Genomics AB's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was -303.03%.
The historical rank and industry rank for Prostatype Genomics AB's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
OSTO:PROGEN'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -581.09 Med: -6.95 Max: 1035.15
Current: -222.22
During the past 7 years, the highest Earnings Yield (Joel Greenblatt) of Prostatype Genomics AB was 1035.15%. The lowest was -581.09%. And the median was -6.95%.
OSTO:PROGEN's Earnings Yield (Joel Greenblatt) % is ranked worse than 97.65% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.21
vs OSTO:PROGEN: -222.22
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Prostatype Genomics AB's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Prostatype Genomics AB (OSTO:PROGEN) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Prostatype Genomics AB Earnings Yield (Joel Greenblatt) % Related Terms
Prostatype Genomics AB Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Prostatype Genomics AB's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostatype Genomics AB Earnings Yield (Joel Greenblatt) % Chart
For the Diagnostics & Research subindustry, Prostatype Genomics AB's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB Earnings Yield (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's Earnings Yield (Joel Greenblatt) % falls into.
Prostatype Genomics AB Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Prostatype Genomics ABs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of -303.03% mean?
Prostatype Genomics AB (OSTO:PROGEN) has a Earnings Yield (Joel Greenblatt) % of -303.03% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Prostatype Genomics AB and its competitors. According to the industry distribution chart, Prostatype Genomics AB ranks #208 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 97.7%.
Is Prostatype Genomics AB's Earnings Yield (Joel Greenblatt) % too high?
Prostatype Genomics AB's current Earnings Yield (Joel Greenblatt) % is -303.03%. Based on the distribution chart, Prostatype Genomics AB ranks #208 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Prostatype Genomics AB has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Earnings Yield (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #208 out of 213 companies for Earnings Yield (Joel Greenblatt) %. This places Prostatype Genomics AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good Earnings Yield (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current Earnings Yield (Joel Greenblatt) % is -303.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.04, compared to a current price of kr0.15 — trading 273.8% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -303.03%. Prostatype Genomics AB's overall GF Score™ is 23/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Earnings Yield (Joel Greenblatt) % is -303.03% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued.
The current stock price of kr0.15 is trading 273.8% above its estimated GF Value™ of kr0.04.
GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.
Key valuation signals for OSTO:PROGEN:
Earnings Yield (Joel Greenblatt) %: -303.03%
GF Value™: kr0.04 vs. price of kr0.15 (273.8% above fair value)
No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
23GF Score
Get the complete analysis for OSTO:PROGEN
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PROGEN has been successfully added to your 
